Airway Therapeutics

  • About Us
  • Pipeline
  • BPD
  • Respiratory & Inflammatory Diseases
  • News
  • Contact

Surfactant protein D influences surfactant ultrastructure and uptake by alveolar type II cells

December 11, 2018 By Airway Therapeutics

Surfactant protein D (SP-D) is a member of the collectin family of the innate host defense proteins. In the lung, SP-D is expressed primarily by type II cells. Gene-targeted SP-D-deficient [SP-D(−/−)] mice have three- to fivefold higher surfactant lipid pool sizes. However, surfactant synthesis and secretion by type II cells and catabolism by alveolar macrophages …

Filed Under: Scientific Publications

Intratracheal Recombinant Surfactant Protein D Prevents Endotoxin Shock in the Newborn Preterm Lamb

December 11, 2018 By Airway Therapeutics

Rationale: The susceptibility of neonates to pulmonary and systemic infection has been associated with the immaturity of both lung structure and the immune system. Surfactant protein (SP) D is a member of the collectin family of innate immune molecules that plays an important role in innate host defense of the lung. Objectives: We tested whether …

Filed Under: Scientific Publications

Correction of Pulmonary Abnormalities in Sftpd/ Mice Requires the Collagenous Domain of Surfactant Protein D

December 11, 2018 By Airway Therapeutics

Surfactant protein D (SP-D) is a member of the collectin family of innate defense proteins. Members of this family share four distinct structural domains: an N-terminal crosslinking domain, a collagenous domain, a neck region, and a carbohydrate recognition domain. In this study, the function of the collagenous domain was evaluated by expressing a SP-D collagen …

Filed Under: Scientific Publications

Surfactant protein-D regulates the postnatal maturation of pulmonary surfactant lipid pool sizes

December 11, 2018 By Airway Therapeutics

Surfactant protein (SP)-D plays an important role in host defense and pulmonary surfactant homeostasis. In SP-D-deficient (Sftpd−/−) mice, the abnormal large surfactant forms seen at the ultrastructural level are taken up inefficiently by type II cells, resulting in an over threefold increase in the surfactant pool size. The mechanisms by which SP-D influences surfactant ultrastructure …

Filed Under: Scientific Publications

Surfactant Protein-D Inhibits Lung Inflammation Caused by Ventilation in Premature Newborn Lambs

December 11, 2018 By Airway Therapeutics

Rationale: Premature newborns frequently require manual ventilation for resuscitation during which lung injury occurs. Although surfactant protein (SP)-D regulates pulmonary inflammation, SP-D levels are low in the preterm lung. Commercial surfactants for treatment of respiratory distress syndrome do not contain SP-D. Objectives: To determine whether addition of recombinant human SP-D (rhSP-D) to commercial surfactant influences …

Filed Under: Scientific Publications

Surfactant Protein D Deficiency Increases Lung Injury during Endotoxemia

December 11, 2018 By Airway Therapeutics

Acute lung injury (ALI) and its severe form, acute respiratory distress syndrome (ARDS), are major causes of acute respiratory failure with high rates of morbidity and mortality. Although surfactant protein (SP)-D plays a critical role in pulmonary innate immunity and several clinical studies suggest that this protein may be implicated in the pathophysiology of ARDS, …

Filed Under: Scientific Publications

Supramolecular Assembly of Human Pulmonary Surfactant Protein SP-D.

December 11, 2018 By Airway Therapeutics

Pulmonary surfactant protein D (SP-D) is a glycoprotein from the collectin family that is a component of the lung surfactant system. It exhibits host defense and immune regulatory functions in addition to contributing to the homeostasis of the surfactant pool within the alveolar airspaces. It is known that the SP-D monomer forms trimers, which further …

Filed Under: Scientific Publications

Airway Therapeutics Announces Appointment of Chief Medical Officer

August 25, 2018 By Airway Therapeutics

(Cincinnati, OH—August 24, 2018) Airway Therapeutics, LLC (“Airway”), a biotechnology company focused on developing new interventions for acute and chronic lung diseases, announces the appointment of Paul Kingma, MD, PhD to the position of Chief Medical Officer (“CMO”) as of August 1, 2018 in preparation for clinical development of AT-100, a recombinant form of human …

Filed Under: News

Airway Therapeutics Closes $11M Series B Round of Financing

May 7, 2018 By Airway Therapeutics

(Cincinnati, OH– April 17, 2018) Airway Therapeutics, a biotechnology company focused on developing new interventions for acute and chronic lung diseases has secured $11 million in Series B financing from new and existing investors. The financing comes as Airway Therapeutics steadily meets milestones in the development of its lead product AT-100, a recombinant form of …

Filed Under: News

Airway Therapeutics, LLC Obtains License on Glycotope Cell Line

September 26, 2017 By Airway Therapeutics

Core Manufacturing Technology is Key Milestone on Airway’s Path to Market Cincinnati, Ohio, 11 September 2017- Airway Therapeutics, LLC, [Airway] a biotech company focused on developing new interventions for acute and chronic lung diseases, today announced an exclusive licensing agreement with the German biotechnology company, Glycotope GmbH [Glycotope]. Under the terms of this agreement, Airway …

Filed Under: News

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
logo

Airway Therapeutics, Inc

1200 Johnson Ferry Rd, Suite 300
Marietta, GA 30068

513.770.9630

  • Privacy

Sitemap

  • Home
  • About Us
  • Pipeline
  • BPD
  • Respiratory & Inflammatory Diseases
  • News
  • Contact
Copyright © 2015 Airway Therapeutics, Inc. All Rights Reserved.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.
Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT
MENU
  • About Us
  • Pipeline
  • BPD
  • Respiratory & Inflammatory Diseases
  • News
  • Contact